Mavorixafor (AMD-070) is a potent, selective and orally availableCXCR4antagonist, with anIC₅₀value of 13 nM againstCXCR4¹²⁵I-SDF binding, and also inhibits the replication of T-tropicHIV-1(NL4.3 strain) in MT-4 cells and PBMCs with anIC₅₀of 1 and 9 nM, respectively.

Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC₅₀value of 13 nM against CXCR4¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2)^[1]. Mavorixafor (AMD-070) (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells^[2].

Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss^[2].

349.47

Solid

C₂₁H₂₇N₅

558447-26-0

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

• 1.

  AMD-070 is prepared in oil plus vehicle (PBS) control^[3].